Bernstein Healthcare Services Disruptors Conference

Boston | November 14, 2017

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on current estimates and assumptions made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

Disrupting Healthcare: From Volume to Value

MACRA	The Medicare Access and CHIP Reauthorization Act (MACRA) contained significant levers to move providers towards the APM goal.
-------	-------------------------------------------------------------------------------------------------------------------------------------

32	Over 30 million patients receive care through accountable
million	care organizations (ACOs) today1.

Source: Leavitt Partners, October 2017

Revenue Profile and New Business Activities

Percentage of Fresenius Medical Care FY 2016 revenue (€, IFRS)

Health care services Products

Therapies & laboratory services for patients with chronic kidney failure

Dialysis Services Dialysis Products Care Coordination

North America - Businesses supporting dialysis, e.g. vascular services

e.g., dialysis machines, dialyzers & bloodline systems

68% 18% 2.2bn 14% 3.1bn

11.3bn

Embracing Healthcare Disruption

Fresenius Medical Care at the Intersections

Nationwide physical infrastructure
Vertical integration
Thought-leader in renal disease
Robust payor infrastructure
Sophisticated data expertise
No "value-based care" conflict

Capability Expansion

Mid-term revenue and growth profile – 2020e

Size of bubble indicates absolute revenue contribution in 2020e. Positioning of bubble illustrative.

The Importance of Value-based Care

Example interventions:

Treatment Options Program
Social Work Intensive
Renal Care Coordination
Volume Management
Rx Therapies
Medication Management
Outlier Rx Management
Patient Experience

Opportunity to Decrease Hospitalization Average Part A & B Cost for Medicare FFS Beneficiary with ESRD, in % Dialysis 41% Other Part B 10% Skilled Nursing 4% Nephrologist 5% Other Part A 12% Transportation 3% Kidney Care Vascular Care Health Partners Pharmacy Our capabilities can drive reductions in patient hospitalizations PMPM \$7,377¹ (~\$90,000 p.a.)

¹ Based on 2016 ESCO benchmark | PMPM = per member per month

End Stage Real Disease Seamless Care Organization (ESCO)

Pilot program through Centers for Medicare and Medicaid Innovation (CMMI)
Launched in October 2015 and running through 2018 with two 1 year extension options
Partnership between nephrologists, dialysis organizations, and other care providers
Accountable for all facets of matched beneficiaries Medicare A/B costs with savings or losses shared between participants and CMMI

Fresenius Seamless Care Quick Facts

	Program Year 1 (2015/2016)	Program Year 2 (20171)
Total ESCOs	13	37
FME ESCOs	6	24
FME Aligned Beneficiary Years	9,172	25,349
Total Program Savings	\$75 million
FME Gross Savings	\$43 million

As of end of 3Q'17

Contacts

FME Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany

Ticker: FME or FMS (NYSE) WKN: 578 580 ISIN: DE00057858002

Dr. Dominik Heger Head of Investor Relations and Corporate Communications Tel.: +49–(0) 6172–609–2601 Email: [email protected]

Robert Adolph

Director Investor Relations Tel.: +49–(0) 6172–609–2477 Email: [email protected]

Philipp Gebhardt

Senior Manager Investor Relations Tel.: +49–(0) 6172–609–7323 Email: [email protected]